Piv­otal fail­ure trig­gers job cuts at San Diego-based Toca­gen

Toca­gen is cir­cling the drain, fol­low­ing the crush­ing late-stage fail­ure of its ex­per­i­men­tal brain can­cer ther­a­py last month. On Thurs­day, the San Diego-based com­pa­ny slashed its work­force by 65%.

Its two-part ther­a­py was be­ing test­ed in pa­tients with re­cur­rent high-grade glioma un­der­go­ing re­sec­tion in the To­ca 5 study. On av­er­age, pa­tients on the Toca­gen reg­i­men ac­tu­al­ly did not live as long as those giv­en stan­dard treat­ment (11.1 months me­di­an com­pared to 12.2 months). In ad­di­tion, the com­pa­ny’s ther­a­py hit a haz­ard ra­tio of 1.06, re­flect­ing an in­creased risk to pa­tients, along with an un­sa­vory p-val­ue of 0.6154.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER